IBD:治疗干预对梅奥内镜评分为1的溃疡性结肠炎的患者具有延长复发的疗效

2019-03-16 不详 MedSci原创

目前,粘膜愈合(MH)被普遍接受作为溃疡性结肠炎(UC)的治疗终点。最近的研究表明,Mayo内镜评分(MES)为1的患者的临床复发率高于MES为0的患者。因此,本项研究旨在证明二者之间的关系。

背景
目前,粘膜愈合(MH)被普遍接受作为溃疡性结肠炎(UC)的治疗终点。最近的研究表明,Mayo内镜评分(MES)为1的患者的临床复发率高于MES为0的患者。因此,本项研究旨在证明二者之间的关系。

方法
本研究纳入了MES为1且部分Mayo评分≤2的UC患者。研究人员从患者行第一次结肠镜检查(CS)开始随访所有患者。研究人员在治疗干预(第一次CS后立即)组和非治疗干预组之间比较临床复发率,并评估复发的危险因素。

结果
研究人员从2013年至2016年期间接受CS的1523名UC患者中筛选了220名患者纳入本研究。治疗干预患者的临床复发率(P = 0.005)和内镜恶化率(P = 0.11)低于无治疗干预的患者。多变量分析显示,在第一次CS后立即没有治疗干预(临床复发P = 0.001,内镜急性加重P = 0.050)和溃疡性结肠炎内镜下严重血管模式评分(P = 0.021,临床复发,P 内镜下恶化= 0.019)是临床复发和内镜下恶化的危险因素。

结论
对于MES为1的UC患者的治疗干预可以预防疾病复发。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1695075, encodeId=429f16950e5bf, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Apr 06 13:22:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262065, encodeId=fe4c126206536, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263515, encodeId=d1a712635158c, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368290, encodeId=9597136829021, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032102, encodeId=584e1032102d8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Mar 16 18:22:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-04-06 nymo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1695075, encodeId=429f16950e5bf, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Apr 06 13:22:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262065, encodeId=fe4c126206536, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263515, encodeId=d1a712635158c, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368290, encodeId=9597136829021, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032102, encodeId=584e1032102d8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Mar 16 18:22:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1695075, encodeId=429f16950e5bf, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Apr 06 13:22:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262065, encodeId=fe4c126206536, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263515, encodeId=d1a712635158c, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368290, encodeId=9597136829021, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032102, encodeId=584e1032102d8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Mar 16 18:22:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-03-18 bnurmamat
  4. [GetPortalCommentsPageByObjectIdResponse(id=1695075, encodeId=429f16950e5bf, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Apr 06 13:22:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262065, encodeId=fe4c126206536, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263515, encodeId=d1a712635158c, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368290, encodeId=9597136829021, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032102, encodeId=584e1032102d8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Mar 16 18:22:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1695075, encodeId=429f16950e5bf, content=<a href='/topic/show?id=c76e6645438' target=_blank style='color:#2F92EE;'>#溃疡性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66454, encryptionId=c76e6645438, topicName=溃疡性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=787129789891, createdName=nymo, createdTime=Sat Apr 06 13:22:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262065, encodeId=fe4c126206536, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263515, encodeId=d1a712635158c, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368290, encodeId=9597136829021, content=<a href='/topic/show?id=8a5e6242257' target=_blank style='color:#2F92EE;'>#梅奥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62422, encryptionId=8a5e6242257, topicName=梅奥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Mar 18 06:22:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032102, encodeId=584e1032102d8, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Mar 16 18:22:00 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-03-16 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

JCC: Vedolizumab可以在中度至重度活动性溃疡性结肠炎患者取得很好的深度缓解

本项研究主要评估了vedolizumab在溃疡性结肠炎患者中诱导深度缓解的效果以及vedolizumab谷浓度与深度缓解率之间的相关性。

BMC Gastroenterology: 中国三级医院溃疡性结肠炎患者艰难梭菌感染的回顾性分析

有文献报道艰难梭菌感染(CDI)对溃疡性结肠炎(UC)患者的影响越来越大。因此,研究人员进行了一项回顾性研究,以确定UC患者CDI的发生率,临床特征,危险因素和预后情况。

GUT: 硫嘌呤对溃疡性结肠炎的自然病史和手术结果的影响

硫唑嘌呤肠被用作溃疡性结肠炎(UC)的维持治疗药物,但是这些药物是否影响该疾病的自然病史尚不清楚。本项研究的目的是评估10年内硫嘌呤在治疗溃疡性结肠炎中对于结肠切除术,住院,疾病程度进展和抗肿瘤坏死因子(TNF)治疗方面的效果。

JCC: 阑尾切除术对于治疗难治性溃疡性结肠炎的疗效分析

阑尾易于发炎,切除阑尾是否可以减少溃疡性结肠炎的发生目前还没有定论。本研究的目的是检验阑尾切除术对治疗难治性溃疡性结肠炎[UC]患者病程的调节作用。

BMC Gastroenterology: 结肠微生物群在溃疡性结肠炎发病机制中的作用

最近有研究发现,肠道微生物群与UC的发病密切相关。目前,关于肠道微生物群的研究主要包括从肠腔收集的样本。然而,管腔菌群只是肠道微生物群的一部分,目前还缺乏对病理条件下粘膜菌群变化的研究。在这项研究中,研究人员调查了UC的发病与不同肠层的菌群变化之间的相关性。

AP&T: Vedolizumab血清浓度与溃疡性结肠炎的临床结果之间的关系

维多珠单抗(Vedolizumab)在治疗溃疡性结肠炎中前景广阔,治疗效果优良。但是目前缺乏前瞻性设计来评估维多珠单抗暴露浓度与疗效反应之间的研究。因此本项研究的主要目的是(a)调整潜在混杂变量后调查维多珠单抗暴露 - 反应关系; (b)提出潜在的目标血清维多珠单抗浓度用于未来的研究; (c)确定早期维多珠单抗血清浓度是否溃疡性结肠炎短期和长期临床结果相关。